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Abstract
Introduction
Although tobacco control activity in the United States
during the past several years has increased dramatically,
tobacco use continues to have devastating consequences
among all age cohorts.
Methods
In November 2003, a survey of tobacco control practices
and policies in health insurance plans was conducted by
America’s Health Insurance Plans’ national technical
assistance office. The survey was the fourth and final sur-
vey conducted as part of the Addressing Tobacco in
Managed Care program. Of the 215 plans in the sample,
160 (74%) completed the survey. Collectively, these plans
represent more than 60 million members of health main-
tenance organizations.
Results
From 1997 to 2003, health insurance plans have demon-
strated increasing use of evidence-based programs and
clinical guidelines to address tobacco use. The number of
plans providing full coverage for any type of pharma-
cotherapy for tobacco cessation has more than tripled since
1997. Plans have also shown substantial improvement in
their ability to identify all or some of their members who
smoke. Similarly, a greater percentage of plans are using
strategies to address smoking cessation during treatment
for other chronic diseases and after acute events such as a
myocardial infarction.
Conclusion
Despite improvements, important opportunities remain
for health insurance plans and other stakeholders to
expand their tobacco control activities and transfer the les-
sons learned to other health problems.
Introduction
The scope and pace of tobacco control activity in the
United States during the past several years has
increased dramatically. Beginning with the 1998 multi-
state tobacco settlement, there has been heightened
attention on tobacco use and an emergence of effective
tobacco control strategies. Still, tobacco use continues to
have devastating consequences among all age cohorts in
the United States. New estimates from the Centers for
Disease Control and Prevention (CDC) indicate that
from 1997 to 2001, approximately 438,000 people in the
United States died prematurely each year as a result of
smoking or exposure to secondhand smoke (1). The most
recent report from the U.S. surgeon general confirms
that smoking harms almost every organ in the body,
causing numerous diseases and reducing overall quality
of life and life expectancy (2). Despite these grim facts,
approximately 23% of American adults continue to
smoke cigarettes (3).
In addition to the health consequences of tobacco use,
it has enormous financial consequences. In 1998, 
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smoking-attributable health care expenditures were
estimated at $75.5 billion (4). More recent data from
1997 to 2001 indicate that smoking costs the United
States approximately $92 billion annually in lost pro-
ductivity (1). Together, the health and financial conse-
quences of tobacco dependence continue to make treat-
ment and prevention of tobacco use a priority among
multiple stakeholders, including health plans, insurers,
providers, employers, and policymakers.
In 1997, the Robert Wood Johnson Foundation (RWJF)
established a collaborative program, Addressing Tobacco
in Managed Care (ATMC). The program was based on
the understanding that health insurance plans’ compre-
hensive benefits, sophisticated information systems,
defined populations, and partnerships with health care
providers are well suited to implement, evaluate, and
sustain tobacco control interventions. The initiative con-
sisted of a national program office (NPO) located at the
University of Wisconsin and the University of Illinois at
Chicago and a national technical assistance office
(NTAO) managed by America’s Health Insurance Plans
(AHIP). The mission of the NTAO was to advance the
integration of tobacco cessation and prevention strate-
gies into routine health care by increasing the number
and quality of tobacco control initiatives within health
insurance plans.
As part of the program, the NTAO provided resources to
health insurers who were striving to develop tobacco con-
trol programs, conducted a benchmarking awards program
to highlight exemplary health plan tobacco control initia-
tives, promoted best practices and partnerships through
national conferences, and oversaw the development of a
business case model for smoking cessation. The NTAO also
conducted four surveys of health plans to assess practices
and policies related to tobacco control. ATMC concluded its
work in fall 2005.
The ATMC baseline survey was conducted in 1997,
followed by similar surveys in 2000 and 2002. The
results of the surveys were published in 1998, 2002,
and 2004 (5-7).  The fourth ATMC survey was con-
ducted in 2003. This paper presents the results of the
2003 ATMC survey, highlights changes from 1997 to
2003, and explores findings and trends in light of
tobacco control activities in the United States during
the same period.
Methods
A 32-item survey instrument was developed and pilot
tested in fall 2003. The instrument was designed to assess
new trends, barriers, and opportunities related to address-
ing tobacco control in health insurance plans, identify new
models or frameworks of care, and assess changes in
health-plan based tobacco control activities between 1997
and 2003. The sample for the survey was drawn from the
687 health insurance plans listed in AHIP’s national data-
base of member and nonmember plans. The database was
stratified based on plan enrollment size, and a random
sample of 247 plans was selected. The sample size enables
the detection of a 5% difference between proportions at α =
.05 and β = .80.
The ATMC survey was conducted in winter 2003. As in
1997, 2000, and 2002, the 2003 ATMC survey was con-
ducted through mail, e-mail, and fax, with telephone fol-
low-up with nonrespondents at 2 weeks, 4 weeks, and 6
weeks after initial contact. The sample included large
national plans that have local plans represented in multi-
ple states. As in previous years, the corporate office of each
national plan was asked to review the questionnaire and
determine whether they would respond on behalf of their
local plans or ask their local plans to complete the ques-
tionnaires individually. Three of four national plans opted
to respond on behalf of their local plans, and their respons-
es reflect 49% (78/160) of the responses. (The three nation-
al plans did not necessarily provide identical responses to
all the survey questions for all their local plans.)
The 2003 survey questionnaire was longer but similar to
the one used in 2002. Of the 32 items in the 2003 ques-
tionnaire, 17 were the same as in previous years; seven
were added to collect more detailed data on areas of inter-
est (e.g., pharmaceutical coverage, attributes of cessation
interventions, strategies for notifying members about ces-
sation benefits, member incentives); two were added to col-
lect data on plans’ use of return-on-investment (ROI)
analysis and interest in ROI analysis tools; two were added
to gain additional insight into key areas (e.g., methods
used to require providers to carry out tobacco control activ-
ities, barriers plans face in addressing tobacco control);
and four were added to enhance understanding of plan
characteristics (e.g., accreditation status, use of Health
Plan Employer Data and Information Set [HEDIS] data).
Because of feedback provided during pretesting, most sur-
vey questions focused on smoking cessation despite recog-
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encompassing terms. The 2003 ATMC survey was origi-
nally designed to capture data about both preferred
provider organizations (PPOs) and health maintenance
organizations (HMOs). However, feedback received during
the initial review of the survey instrument suggested that
the high degree of variability in the PPO industry (risk and
nonrisk bearing) made it difficult for plans to reliably
respond to survey questions. As a result, the 2003 ATMC
survey remained focused on the HMO product (as it had
been for the previous surveys) and asked respondents to
answer all questions based on their best-selling commer-
cial HMO product.
All analyses were performed with SPSS software (SPSS,
Inc, Chicago, Ill). Chi-square tests and t tests were used for
comparisons, and results of these tests were considered
statistically significant when the corresponding P value
was .05 or less. Consistent with previous years, the data
were unweighted to best describe the policies and practices
of health insurance plans.
Results
Of the 247 health plans in the sample, 32 were excluded
because they were no longer in business or did not offer a
commercial HMO product. Of the 215 valid plans, 160
(74%) completed and returned the survey. Collectively, the
160 plans represented more than 60 million HMO mem-
bers. Respondent plans were predominantly network
(48%) and mixed models (33%). Sixty-eight percent were
for-profit and publicly held, 8% were for-profit and pri-
vately held, 23% were not-for-profit, and 1% were mutual
companies. A comparative analysis of respondents and
nonrespondents indicated that there were no significant
differences in size, tax status, or predominant model type
between respondents and nonrespondents.
Among respondent plans, 67% reported having a written
clinical guideline for smoking cessation (Table 1). Among
these plans, approximately one third reported using either
the 2000 U.S. Public Health Service (PHS) Guideline on
Tobacco Use and Dependence (8) or the 1996 Agency for
Health Care Policy and Research (AHCPR) Practice
Guideline on Tobacco Cessation (9). More than one fourth
of plans reported having a guideline that had been inter-
nally developed. Among plans that reported having an
internally developed guideline, almost all (92%) reported
that their guideline was based on either the PHS or
AHCPR guideline (data not shown). In addition, more than
one third of plans with a guideline reported that their
guideline came from another source (e.g., disease-manage-
ment vendors, state coalitions, collaborations).
Almost all plans indicated that they could identify some
or all individual plan members who smoke (Table 1).
Although only 3% of plans indicated that they could iden-
tify all members who smoke, 89% reported that they could
identify at least some of their members who smoke (data
not shown). Among the plans that reported being able to
identify smokers, the most common data sources were
health-risk appraisals and telephone surveys. A relatively
small percentage of plans (12%) reported using enrollment
data to identify smokers. The same percentage of plans
reported being able to identify smokers through registries
that documented smoking status.
The vast majority (88%) of respondent plans indicated
that they provided full coverage (defined as no additional
charge for the member outside of the member’s normal
copayment for office visits) for at least one type of phar-
macotherapy used for tobacco cessation (data not shown).
Bupropion in the form of Wellbutrin was the most com-
monly covered pharmacotherapy (83%) (Table 1).
Full coverage for at least one type of behavioral inter-
vention used for tobacco cessation was reported by most
(72%) health plans (data not shown). Self-directed online
resources were the most commonly covered behavioral
interventions, followed by other self-help materials, indi-
vidual counseling during pregnancy, and telephone coun-
seling (Table 1).
Health plans reported having various strategies to
encourage members to stop smoking during times that
might be considered important teachable moments (Table
1). Almost all plans (91%) reported having a strategy for
addressing smoking cessation while a member was partic-
ipating in one of the plan’s disease-management programs.
Most health plans also reported having a strategy for
addressing smoking cessation during pregnancy (69%),
during treatment for chronic illnesses (65%), and following
a myocardial infarction (56%).
Plans reported using several types of strategies with
providers and their office staff to encourage smoking cessa-
tion among plan members. Approximately half of plans
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reported offering provider education, and almost one fourth
of plans reported using provider prompts and reminders
(Table 1). Provider prompts and reminders were coupled
with provider education by 21% of plans (data not shown).
Although health plans reported various health system
barriers to their ability to effectively address tobacco con-
trol, the most common barriers were related to resources
(e.g., inadequate staff, funding, competing priorities) and
system issues (e.g., poor data collection, reporting, record
maintenance). Other important barriers reported by more
than half of plans included lack of provider compliance,
lack of purchaser demand, and delayed economic return on
investment (Table 1).
Approximately 39% of plans reported that they current-
ly perform some type of ROI analysis on at least some of
their tobacco cessation activities (data not shown). Almost
all plans (94%) indicated that they would be interested in
using an ROI analysis tool designed for tobacco cessation if
one were available.
Several tobacco control activities seem to be more likely
to occur in larger plans than in smaller plans (Table 2).
Based on the enrollment distribution of health plans in our
sample, we defined larger plans as those with more than
250,000 members and smaller plans as those with 250,000
members or fewer. Larger plans were more likely than
smaller plans to have a written clinical guideline for smok-
ing cessation (P < .001) and to have a strategy for address-
ing smoking cessation during specific times, such as during
adolescence, pregnancy, and postpartum visits and pedi-
atric visits, after a myocardial infarction, and during treat-
ment for other chronic illness (P ranged from < .001 to
.04). We found no differences in the extent to which small-
er and larger plans provided full coverage for pharma-
cotherapies used for smoking cessation. Although smaller
plans were more likely to report providing full coverage for
some types of behavioral interventions, such as telephone
counseling and face-to-face counseling (P < .001), larger
plans were more likely to report providing full coverage for
self-help materials (P = .01) and individual counseling of
pregnant women (P = .02). Smaller plans were also more
likely to report having annual or lifetime limits on cover-
age for smoking cessation interventions (P < .001).
Although the survey instruments used in the 1997, 2000,
2002, and 2003 ATMC surveys were not identical, a core
set of questions on pharmacotherapies, behavioral health,
and smoking cessation strategies remained unchanged
(Table 3). The percentage of plans that provided full cover-
age for any type of pharmacotherapy used for smoking ces-
sation increased from 25% to 88% from 1997 to 2003 (P <
.001). A large increase was also noted in the percentage of
plans able to identify individual smokers: from 15% in
1997 to 91% in 2003 (P < .001).
Full coverage of behavioral interventions, such as coun-
seling and self-help materials, fluctuated from 1997 to
2003 (Table 3). For example, more than half of the plans in
the 1997 and 2000 surveys reported full coverage for self-
help materials, but only one fourth of plans reported simi-
lar coverage in 2002, and the percentage of plans reporting
full coverage for self-help materials increased to nearly
50% in 2003. Similarly, the 2002 survey indicated a statis-
tically significant increase in the number of plans provid-
ing full coverage for telephone counseling, but the results
of the 2003 survey showed a decrease in coverage
(although the changes were not statistically significant
across all 4 years of the survey).
From 1997 to 2003, the percentage of plans with strate-
gies to address smoking cessation after a myocardial
infarction increased from 22% to 56% (P < .001) and from
23% to 65% during treatment for other chronic diseases (P
< .001) (Table 3). Increases in the percentage of plans with
a strategy to address smoking cessation during postpar-
tum visits (to prevent relapse) were found from 1997 to
2002 and sustained in 2003 (P = .03).
Discussion
From 1997 to 2003, health plans demonstrated increas-
ing use of evidence-based programs and clinical guidelines
to address tobacco use. Clinical guidelines detail the most
effective options for helping patients to quit smoking, and
use of strategies recommended in clinical guidelines is
associated with greater success in helping smokers to quit
(9,10). Although most health plans reported having a writ-
ten clinical guideline for tobacco cessation, it is possible
that even more plans address tobacco cessation within
other clinical guidelines used for managing or treating con-
ditions in which tobacco use is identified as a comorbidity
or risk factor (i.e., asthma, heart disease, and diabetes).
Slightly more than one fourth of the plans with a clinical
guideline for tobacco cessation reported using the PHS
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internally developed guideline, almost all (92%) reported
that their guideline was based on either the PHS or
AHCPR guideline. Interestingly, nearly two thirds of plans
reported that their written clinical guideline was based on
or developed from a source other than the PHS or AHCPR.
A review of the qualitative data provided by plans in
response to this question indicated that many of the plans
are using guidelines developed by disease-management
vendors and various state coalitions and collaborations.
This finding lends further support to the idea that health
plans may be increasingly incorporating their tobacco ces-
sation activities into the broader set of activities and guide-
lines that they use for the management of diseases related
to tobacco use (i.e., asthma, heart disease, and diabetes).
Plans have shown tremendous improvement since 1997
in identifying individual plan members who smoke. The
ability to identify smokers is an important indicator of a
plan’s ability to remind or prompt providers to discuss or
advise patients about smoking cessation and also commu-
nicate with members about their health plan’s cessation
programs and benefits. Provider reminders are considered
to be an effective strategy for supporting smoking cessa-
tion and are recommended by the Task Force on
Community Preventive Services (10).
In the 2003 ATMC survey, the response choices to the
question “Can your plan identify individual members who
smoke?” were revised slightly to allow plans to indicate
whether they could identify all members who smoke or
some members who smoke. The results of the 2003 survey
indicate that although almost all plans can identify indi-
vidual members who smoke, only 3% reported being able
to identify all members who smoke, and 89% reported
being able to identify some members who smoke.
Information provided by plans on the methods they use to
identify smokers also indicates that they are most likely to
identify subgroups of smokers (i.e., people who respond to
health-risk appraisals or surveys). Although it would be
ideal for plans to identify all smokers and intervene with
each individually, identifying all members of any subgroup
engaging in a health behavior would be a challenge for any
organization.
The number of health plans providing full coverage for
any type of pharmacotherapy for tobacco cessation has
more than tripled since 1997. In the 2003 ATMC survey,
almost nine out of 10 plans reported providing full cover-
age for at least one type of pharmacotherapy for tobacco
cessation. Consistent with recommendations based on the
effectiveness of various prescription and over-the-counter
tobacco cessation first-line pharmacotherapies (9), most
plans reported providing full coverage for at least one form
of bupropion (Wellbutrin). The significant increase in the
number of plans that provide full coverage for at least one
type of pharmacotherapy for tobacco cessation is well
aligned with the growing body of literature indicating that
reduced out-of-pocket cost is associated with greater use of
tobacco cessation programs and services (11,12) and may
lead to increased rates of cessation (13).
Given the literature citing the effectiveness of telephone
counseling and indicating that smokers are more likely to
use telephone counseling than to participate in individual
or group counseling sessions (14,15), it is not surprising
that more plans in 2002 reported offering full coverage for
telephone counseling than in 1997. However, the results of
the 2003 ATMC survey indicate that fewer plans in 2003
are providing full coverage for telephone counseling than
in 2002. Although the survey did not assess reasons for
offering or not offering specific types of interventions, it is
possible that increased availability of local or state-spon-
sored quit lines has resulted in less need for health plans
to provide coverage for telephone counseling.
The fact that 91% of plans reported having a strategy for
addressing tobacco cessation with patients already partic-
ipating in disease-management programs underscores the
importance of promoting disease-management programs
as a vehicle for addressing tobacco cessation. In environ-
ments where numerous health improvement programs
must compete for limited resources, the ability to effective-
ly address tobacco cessation within the context of other
programs may be strategically and clinically important.
Indeed, most plans have strategies for addressing tobacco
cessation during pregnancy, when a patient is being treat-
ed for a chronic illness, and after acute events such as
myocardial infarction, suggesting that plans are moving in
this direction.
Health plans continue to report that resource limita-
tions, including too few staff and inadequate funding, are
leading barriers to adequately addressing tobacco control.
Although just over one third of plans reported conducting
any type of ROI analysis on their tobacco cessation activi-
ties in 2003, there was widespread interest in identifying
and using ROI analysis tools for tobacco cessation.
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Fortunately, research supported by the NTAO has
recently resulted in the development of a Web-based ROI
analysis tool for smoking cessation interventions based
primarily on smoking-attributable costs to health plans
(16). The ROI tool should be especially useful to health
plans that need to rationalize their investments in smok-
ing cessation interventions or convince purchasers of the
value of such interventions.
Limitations
The ATMC survey and its findings have limitations. The
response rate of approximately 74% is respectable but still
leaves open the possibility of selection bias. Although no
significant differences were detected between respondents
and nonrespondents on three key characteristics (size, tax
status, and predominant model type), respondents may
possibly differ from nonrespondents in ways that were not
measured (e.g., level of interest, commitment to tobacco
control). Another limitation to the ATMC survey is that
the psychometric properties of the questionnaire were not
tested to assess reliability or validity. However, the survey
design process did include pretesting to increase the prob-
ability of including questions that were reliable and likely
to yield valid responses. Additionally, we identified a
potential limitation of the 1997 survey — it did not include
a frame of reference for product type — and corrected all
subsequent ATMC surveys accordingly. Based on inquiries
made to plans following the 1997 survey, we learned that
when a frame of reference is not provided, the tendency is
to base answers on the best-selling HMO product, and this
is what respondents were explicitly asked to do in 2000,
2002, and 2003. However, there is still a possibility that
the change in frame of reference contributed to some of the
differences in survey findings between the 1997 survey
and more recent surveys (but not between the 2000, 2002,
or 2003 surveys).
Few surveys other than the ATMC surveys have been
designed to assess tobacco control practices and policies of
health plans. Of those that have been conducted and pub-
lished, some have focused on plans that operated only in a
single state (12,17); some have included only a narrow sub-
set of plans (i.e., well-established, nonprofit plans with a
history of offering tobacco cessation programs) (18); and
others have collected information only about subsets of
smokers within a plan (i.e., pregnant women) (19,20).
Despite their more limited scope, these surveys have yield-
ed data comparable to the data from the ATMC surveys.
Conclusion
The results of the 2003 ATMC survey indicate that an
increasing number of health plans are using evidence-
based approaches and strategies to address tobacco use
among members. Although almost all plans reported that
their tobacco control activities were limited by resource
and systems barriers, they have been able to sustain the
improvements made since 1997. Even so, many plans may
benefit from taking advantage of the recently developed
ROI analysis tool to leverage the body of literature that
supports the cost-effectiveness of tobacco cessation treat-
ment and advocate for the resources necessary to sustain
their tobacco control activities (8,21-23).
As others have previously noted, health plans play an
important role in tobacco control (24). In particular, plans
continue to be in a unique position to implement opera-
tional policies and programs that can reduce the preva-
lence of tobacco use and improve the health of millions of
people. In addition to their role in sustaining and expand-
ing access to tobacco cessation treatments and services,
health plans should continue to model new tobacco cessa-
tion benefits, promote them widely to their membership,
and influence large purchasers of health care services by
communicating the value of tobacco cessation services.
New opportunities to participate in policy initiatives that
support tobacco control and promote public health are
essential next steps to maintain the availability of these
services over the long term.
It is unclear whether the findings fom the 2003 ATMC
survey apply to other forms of health insurance, such as
PPOs. Unlike HMOs, which have traditionally empha-
sized preventive health care and wellness activities such
as smoking cessation, PPOs have emphasized network
size, expertise, and discounted access to network
providers for members. Although some health insurance
companies are likely to offer the same tobacco control
programs in both their PPO and HMO products, others
may vary their tobacco control programs and policies by
product or purchaser.
Nevertheless, the lessons learned in tobacco control
should be applied to other areas where behavioral health
modification is a core component in the treatment of the
illness or condition. We agree with others who have stat-
ed that one of the most important lessons to be learned
from tobacco control is that tackling similar conditions
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resourced, multidimensional effort (25). Additional les-
sons may include recognition of the importance of being
able to identify individuals in need of services, offering
coverage for effective pharmacotherapies and treatments,
and incorporating programs (such as those for tobacco ces-
sation and obesity) into existing disease-management pro-
grams for which tobacco use and obesity are risk factors or
common comorbidities.
The period from 1997 to 2003 was an active and signifi-
cant time for tobacco control at the local, state, and nation-
al levels. During these 7 years, health plans accomplished
a great deal and demonstrated a strong commitment to
smoking cessation with proven results. Yet there are still
many important opportunities for health plans to advance
their tobacco control activities and to transfer the lessons
learned in tobacco control to other important public health
priorities. Health plans and other stakeholders should look
ahead to the coming years for opportunities to continue
their collaborative efforts to improve the health of individ-
uals and populations.
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and does not imply endorsement by any of the groups named above.Plan has a written clinical guideline for smoking cessation 66.6
Among plans with a written clinical guideline for smoking cessation
Plan uses the 2000 U.S. Public Health Service Guideline (8) 28.3
Plan uses an internally developed clinical guideline 27.4
Plan uses the 1996 Agency for Health Care Policy and Research  7.5
Guideline (9)
Plan uses a guideline from some other source 36.8
Plan is able to identify some or all members who smoke 91.1
Among plans that can identify smokers, data sources used by plans to
identify individual members who smoke
Health-risk appraisal 64.7
Telephone survey 59.3
Mail-based survey 34.1
Medical record review (random sample) 18.7
Administrative data review 16.5
Electronic medical record 15.4
Enrollment information 12.1
Registry containing smoking status 12.1
Plan provides full coverage for
Bupropion (as Wellbutrin) 83.3
Bupropion (as Zyban) 29.5
Prescription NRT nasal spray 19.2
Prescription NRT inhaler 19.2
Prescription NRT patches 18.6
Over-the-counter NRT patches 9.6
Over-the-counter NRT gum 7.7
Over-the-counter NRT lozenges 6.4
Plan provides full coverage for
Self-directed, online resources (interactive and noninteractive) 56.4
Self-help materials (booklets, videos, audiotapes, customized  45.5
mailings)
Individual counseling of pregnant women 44.2
Telephone counseling 42.3
Individual face-to-face counseling 35.9
Group counseling or classes 21.2
Plan has annual or lifetime limits on coverage for smoking  19.3
cessation interventions
Plan allows patients to self-refer to smoking cessation  48.8
services
Plan has a strategy to address smoking cessation
During participation in disease-management programs 91.0
During pregnancy 68.6
During treatment for other chronic illness 64.7
After myocardial infarction 56.4
During postpartum visits (relapse prevention) 46.8
During adolescence 32.1
During pediatric visits (secondhand smoke) 29.5
During hospitalizations 11.5
Plan funds a full- or part-time tobacco control program  16.1
staff position
Plan used the following strategies with members in the past year to
inform them about cessation benefits or encourage them to take advan-
tage of covered treatments
General member education (e.g., newsletters, Web site,  60.0
announcements)
Customized member education (e.g., mailings directed at  31.0
members meeting criteria or conditions)
Increased availability of smoking cessation programs and  22.6
interventions
Discounts or reimbursements for NRT 21.3
Discounts or reimbursements for community resources 14.8
Plan used the following strategies with providers, office staff, or both in
the past year to promote smoking cessation
Provider education 51.9
Prompts and reminders to encourage providers to address 
tobacco control 22.4
Elimination of preauthorization requirements for smoking 
cessation interventions 9.1
Incentives for providers and their staff to effectively address  7.7
tobacco
Increased reimbursement for smoking cessation counseling  3.9
and assistance
Increased amount of time that providers spend with patients 0.6
Barriers to addressing tobacco control among plans
Resource barriers (e.g., staff, funding, competing priorities) 92.9
System barriers (e.g., data collection, data reporting, record  87.7
maintenance)
Delayed economic return on investment 61.3
Lack of purchaser demand 54.5
Lack of provider compliance 54.2
Lack of patient demand 42.6
Tables
Table 1. Results from the 2003 Addressing Tobacco in Managed Care Survey (N = 160)
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Activity % Yes Activity % Yes
NRT indicates nicotine replacement therapy.VOLUME 3: NO. 3
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Table 2. Tobacco Control Activities by Size of Health Plan, 2003 Addressing Tobacco in Managed Care Survey (N = 160)
Plan has a written clinical guideline for smoking cessation 25.4 61.5 <.001
Plan provides full coverage for
NRT over-the-counter gum 5.1 9.3 .34
NRT over-the-counter patches 8.5 10.3 .71
NRT inhalers 20.3 18.6 .78
NRT nasal spray 20.3 18.6 .78
Bupropion (as Zyban) 37.3 24.7 .10
Bupropion (as Wellbutrin) 83.1 83.5 .94
Plan provides full coverage for
Telephone counseling 74.6 22.7 <.001
Face-to-face counseling 69.5 15.5 <.001
Group counseling or classes 28.8 16.5 .07
Individual counseling of pregnant women 32.2 51.5 .02
Self-help materials 32.2 53.6 .01
Plan has annual or lifetime limits on coverage for smoking cessation  25.8 15.5 <.001
interventions
Plan allows patients to self-refer to smoking cessation services 50.9 47.0 .67
Plan is able to identify individual members who smoke 88.4 92.8 .56
Plan has a strategy to address smoking cessation
During adolescence 22.0 38.1 .04
During pregnancy 40.7 85.6 <.001
During postpartum visits (relapse prevention) 11.9 68.0 <.001
During pediatric visits (second hand smoke) 13.6 39.2 .001
After myocardial infarction 25.4 75.3 <.001
During treatment for other chronic illness 37.3 81.4 <.001
During hospitalizations 15.3 9.3 .26
Plan funds a tobacco control program staff position 22.4 12.4 .14
NRT indicates nicotine replacement therapy.
aProportions were compared using the chi-square test; results were considered statistically significant at P <.05.
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<250,000 >250,000 
Plan Members Plan Members
Activity (N = 63), % Yes (N = 97), % Yes P ValueaTable 3. Comparison of Data from the 1997, 2000, 2002, and 2003 Addressing Tobacco in Managed Care Surveysa
Plan provides full coverage for
Any pharmacotherapy for smoking cessation 25.0 20.0 88.8 87.8 <.001
Bupropion (as Zyban) 17.6 37.2 41.1 29.5 .10
Any over-the-counter NRT 6.6 14.9 8.6 9.6 <.001
NRT only with program enrollment 25.0 26.0 10.8 19.3 .01
Plan provides full coverage for
Telephone counseling 32.8 36.8 51.7 42.3 .07
Face-to-face counseling 26.6 23.6 41.1 35.9 .04
Group counseling or classes 35.7 37.0 15.9 21.2 .002
Self-help materials 54.1 56.6 25.8 45.5 <.001
Any behavioral therapy or pharmacotherapy 75.0 94.4 98.0 96.2 <.001
Plan is able to identify individual  14.9 27.1 71.7 91.1 <.001
members (some or all) who smoke
Plan has a specific strategy to address smoking cessation
During adolescence 17.6 24.2 28.9 32.1 .46
During pregnancy 45.0 59.0 56.6 68.6 .08
During postpartum visits 13.6 30.5 46.7 46.8 .03
During pediatric visits 15.8 17.3 28.3 29.5 .10
After myocardial infarction 21.7 27.2 46.7 56.4 <.001
During treatment for chronic illness 22.6 31.3 52.0 64.7 <.001
Plan funds a full- or part-time tobacco  7.7 23.5 19.1 16.1 <.001
control program staff position
NRT indicates nicotine replacement therapy.
aAlthough the survey instruments used in the 1997, 2000, 2002, and 2003 Addressing Tobacco in Managed Care surveys were not identical, a core set of
questions on pharmacotherapies, behavioral health, and smoking cessation strategies remained unchanged.
bProportions were compared for 1997 and 2003 surveys using the chi-square test; results were considered statistically significant at P < .05.
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1997 Respondents 2000 Respondents 2002 Respondents 2003 Respondents
Activity (N = 323), % Yes (N = 85), % Yes (N = 152), % Yes (N = 160), % Yes P Valueb